Commentary|Podcasts|March 29, 2024
A Further Examination of Pharmacy Benefit Managers
Author(s)Nicholas Saraceno, Editor
Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.
Advertisement
In this exclusive PC Podcast interview, Brandon Newman, Xevant’s CEO and founder, explores:
- The implications of the Inflation Reduction Act’s price negotiation provisions, and how these could result in ripple effects across the healthcare system
- The role that pharmacy benefit managers (PBMs) and other intermediaries' play when it comes to determining drug costs, and how spread pricing is involved
- How Xevant helps improve drug cost transparency efforts
- Strategies for affordability Newman would offer the pharma industry that can be implemented immediately
The latest episode of The Pharmaceutical Commerce Podcast is available directly on
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Novo Nordisk’s Bloomington Plant Receives FDA OAI Designation Following Contamination and Compliance Issues
2
Pharma Pulse: Kaiser Permanente Strike Escalates, Takeda Partners with Nabla Bio, and FDA Flags Novo Nordisk Bloomington Site
3
United States Delays Tariffs on Singapore’s Pharma Exports Amid Ongoing Trade Negotiations
4
How Healthcare Organizations Can Balance Federal and State AI Regulations
5
